1-(4-Methylphenyl)-4-penten-1-ol | 125997-12-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-Methylphenyl)-4-penten-1-ol
• 英文别名: 1-(p-tolyl)pent-4-en-1-ol；1-p-tolylpent-4-en-1-ol；1-(4-methylphenyl)pent-4-en-1-ol
• CAS: 125997-12-8
• 化学式: C₁₂H₁₆O
• 分子量: 176.258
• InChiKey: YEPHMNQDHBUULF-UHFFFAOYSA-N

物化性质

• 沸点：
  288.5±9.0 °C(Predicted)
• 密度：
  0.971±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-Methylphenyl)-4-penten-1-ol 在 manganese(IV) oxide 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 2-(p-tolyl)hexa-1,5-diene
  参考文献：
  名称：

  Incorporation of 2-Arylhexa-1,5-diene into Pentasil Zeolite:  A Distorted 1-Arylcyclohexane-1,4-diyl Radical Cation at Room Temperature

  摘要：

  Incorporation into a redox-active pentasil zeolite [(Na,H)-ZSM-5] converted 2-arylhexa-1,5-dienes (9a-c; aryl = phenyl, tolyl, anisyl) into 1-arylcyclohexane-1,4-diyl radical cations, 10a-c(.+). The ESR spectra of 10a-c(.+) (six lines, g = 2.0026; a = 9.0 G) indicated the presence of five essentially equivalent nuclei, indicating limited delocalization of spin and charge into the phenyl group. Sequestered in the pores of ZSM-5, the three species 10a-c(.+) are stable at room temperature, in striking contrast to the parent radical cation in cryogenic matrices: cyclohexane-1,4-diyl radical cation is converted to cyclohexene radical cation above 90 K. The structures of radical cation 10a(.+) (X = H) and of the unsubstituted parent were probed by density functional theory (DFT) and ab initio calculations.

  DOI：

  10.1021/jp046877s
• 作为产物：
  描述：

  4-戊烯酰氯 在 sodium tetrahydroborate 、 iron(III)-acetylacetonate 、 乙醇 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 生成 1-(4-Methylphenyl)-4-penten-1-ol
  参考文献：
  名称：

  Iron-catalysed, general and operationally simple formal hydrogenation using Fe(OTf)₃ and NaBH₄

  摘要：

  已开发出一种操作简单且环境友好的正规氢化方案，使用高丰度的铁（III）盐和廉价、台面稳定、化学计量还原剂NaBH4，在乙醇中，在常温下进行。

  DOI：

  10.1039/c4ob00945b

文献信息

• Highly Enantioselective Construction of Dihydrooxazines via Pd-Catalyzed Asymmetric Carboetherification
  作者：Na Li、Baozhen Sun、Shuang Liu、Jinbo Zhao、Qian Zhang

  DOI：10.1021/acs.orglett.9b04123

  日期：2020.1.3

  Pd-catalyzed asymmetric carboetherification of γ,δ-alkenyl oximes with (hetero)aryl and alkenyl halides in the presence of a commercially available bisphosphine ligand. The enantioenriched products can be facilely converted to functionalized alcohols with high fidelity of chiral transfer.

  在市售双膦存在下，Pd催化γ，δ-烯基肟与（杂）芳基和烯基卤化物的不对称碳醚化反应，可以实现高度对映体富集的5,6-二氢-4H-1,2-恶嗪的直接合成。配体。富含对映体的产物可以容易地转化为具有高保真度的手性转移的官能化醇。
• Copper‐Catalyzed Cope‐Type Hydroamination of Nonactivated Olefins toward Cyclic Nitrones: Scope, Mechanism, and Enantioselective Process Development
  作者：Mengru Zhang、Shuang Liu、Hexin Li、Yajing Guo、Na Li、Meihui Guan、Haroon Mehfooz、Jinbo Zhao、Qian Zhang

  DOI：10.1002/chem.201902683

  日期：2019.9.25

  remains underdeveloped. Herein we report the copper-catalyzed Cope-type hydroamination of oximes with pendant nonactivated olefins, which enables facile access to a series of five- and six-membered cyclic nitrones under mild conditions. In this study, heterocycle-tethered oximes were employed in the Cope-type hydroamination reaction for the first time. High enantioselectivity was achieved for carbon-tethered

  环状硝酮的催化合成，对于合成化学和相关领域而言是重要的功能分子类型，但仍未得到开发。在本文中，我们报告了铜与悬垂的非活化烯烃进行肟的铜催化的Cope型加氢胺化反应，这使得在温和条件下易于获得一系列五元和六元环状硝酮。在这项研究中，第一次将杂环系肟用于Cope型加氢胺化反应。碳连接的γ，δ-乙烯基肟实现了高对映选择性，从而提供了对映体富集的五元环硝酮。初步机理研究的结果表明，在大温度范围内，单核催化物种和统一的催化途径。
• Cyclization of aminyl radicals generated by anodic oxidation of lithium alkenylamides. Stereo- and regioselective synthesis of cis-l-alkyl-2, 5-disubstituted pyrrolidines
  作者：Masao Tokuda、Yasufumi Yamada、Toshiya Takagi、Hiroshi Suginome、Akio Furusaki

  DOI：10.1016/s0040-4020(01)89956-7

  日期：——

  regioaelective cyclization to give -1-alkyl-2, 5-disubatituted pyrrolidines (5c–5h) in moderate yields. The stereochemistry of 5c–5h was confirmed by comparison with the corresponding -1-allkyl-2, 5-disubstituted pyrrolidines which were prepared by aminomercuration of 1c–1h. The structure of -1,2-dimethyl-5-phenylpyrrolidine (17) was established by an X-ray crystallographic analysis of its ammonium bromide

  发现由烯基锂锂（2）的阳极氧化产生的中性氨基自由基（3）经历了立体和区域电环化反应，从而以中等收率得到了-1-烷基-2,5-二取代的吡咯烷（5c-5h）。通过与1c-1h的氨基汞合成制备的相应的-1-烷基-2，5-二取代的吡咯烷进行比较，证实了5c-5h的立体化学。通过对其溴化铵21进行X射线晶体学分析，确定了-1,2-二甲基-5-苯基吡咯烷（17）的结构。。在这项研究中检查的各种氨基自由基被发现仅与它们的双键内部碳原子结合，形成一个五环（5a-5l）或六元环（13）。从N-甲基-1-苯基丁-3-烯基胺（14）没有获得由环化产生的产物。
• Aminyl radical cyclization by means of anodic oxidation. Stereoselective synthesis of -1-methyl-2,5-disubstituted pyrrolidines
  作者：Masao Tokuda、Yasufumi Yamada、Toshiya Takagi、Hiroshi Suginome、Akio Furusaki

  DOI：10.1016/s0040-4039(00)95132-3

  日期：1985.1

  Neutral aminyl radicals generated by anodic oxidation of lithium alkenylamides 2 undergo a stereoselective cyclization to give -1-methyl-2,5-disubstituted pyrrolidines 4. Their stereochemistry was confirmed by a comparison with -1,2-dimethyl-5-phenylpyrrolidine, the structure of which was established by X-ray crystallographic analysis of its quarternary ammonium bromide 6.

  由烯基酰胺锂2的阳极氧化产生的中性氨基自由基经过立体选择性环化，得到-1-甲基-2,5-二取代的吡咯烷4。通过与-1,2-二甲基-5-苯基吡咯烷进行比较，证实了它们的立体化学。其结构是通过对其季铵溴化物6进行X射线晶体学分析确定的。
• [EN] CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD<br/>[FR] PYRIMIDINE-4 CARBOXAMIDES CYCLIQUES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CCR2 POUR LE TRAITEMENT D'INFLAMMATIONS, DE L'ASTHME ET DES BRONCHO-PNEUMOPATHIES CHRONIQUES OBSTRUCTIVES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010070032A1

  公开（公告）日：2010-06-24

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, =CH-, -CH2-, -O-, -S-, and -NH-; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.

  本发明涉及用于治疗疾病和疾病的新型CCR2（CC趋化因子受体2）拮抗剂及其用途，特别是用于治疗肺部疾病如哮喘和慢性阻塞性肺病的药物。公式（I），其中A从单键，=CH-，-CH2-，-O-，-S-和-NH-中选择；其中n为1、2或3；其中Z为C或N，其他变量如声明中所定义，以及以药理学上可接受的酸的酸盐形式存在。